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ABSTRACT
Autologous hematopoietic stem cell transplantation (autoSCT) is an effective treatment for patients with various
hematologic malignancies. Despite the significant improvement in the overall outcome, disease progression after
transplantation remains the major cause of treatment failure. With longer follow-up, therapy-related myelodys-
plasia/acute myelogenous leukemia is becoming an important cause of treatment failure. The prognosis for these
2 groups of patients is very poor. Allogeneic hematopoietic stem cell transplantation (alloSCT) is a potential
curative treatment for these patients. However, the outcome with conventional myeloablative alloSCT after failed
autoSCT is typically poor because of high transplant-related mortality. In an attempt to reduce the treatment-
related toxicity, we studied a reduced-intensity conditioning regimen followed by alloSCT for patients with
progressive disease or therapy-related myelodysplasia/acute myelogenous leukemia after autoSCT. This report
describes the outcomes of 28 patients with hematologic malignancies who received a reduced-intensity alloSCT
after having treatment failure with a conventional autoSCT. Fourteen patients received a hematopoietic stem cell
transplant from a related donor and 14 from an unrelated donor. The conditioning regimen consisted of low-dose
(2 Gy) total body irradiation with or without fludarabine in 4 patients and the combination of melphalan (140
mg/m2) and fludarabine in 24. Cyclosporine and mycophenolate mofetil were used for posttransplantation immu-
nosuppressive therapy, as well as graft-versus-host disease (GVHD) prophylaxis, in all patients. All patients
engrafted and had >90% donor chimerism on day 100 after SCT. Currently, 13 patients (46%) are alive and disease
free, 7 patients (25%) developed disease progression after alloSCT, and 8 (32%) died of nonrelapse causes. Day 100
mortality and nonrelapse mortality were 25% and 21%, respectively. With a median follow-up of 24 months for
surviving patients, the 2-year probabilities of overall survival, event-free survival, and relapse rates were 56.5%,
41%, and 41.9%, respectively. Six patients (21%) developed grade III to IV acute GVHD. Among 21 evaluable
patients, 15 (67%) developed chronic GVHD. We conclude that (1) reduced-intensity alloSCT is feasible and has
an acceptable toxicity profile in patients who have previously received autoSCT and that (2) although follow-up was
short, a durable remission may be achieved in some patients who would otherwise be expected to have a poor
outcome.
© 2003 American Society for Blood and Marrow Transplantation
KEY WORDS
Reduced intensity ● Allogeneic stem cell transplantationw
d
mNTRODUCTION
Autologous hematopoietic stem cell transplanta-
ion (autoSCT) is an effective treatment for patients m
B&MTith various hematologic malignancies. The proce-
ure is well tolerated; most recent series report treat-
ent-related mortality of 5%. Most of the treat-oi:10.1016/S1083-8791(03)00241-6ent failures after autoSCT are due to disease
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progression, particularly for patients who had ad-
vanced disease at the time of transplantation (ie, re-
lapsed or refractory disease). In contrast, allogeneic
hematopoietic stem cell transplantation (alloSCT) is
associated with higher incidence of treatment-related
mortality but improved disease control when com-
pared with autoSCT. The lower relapse rates after
alloSCT are thought to be related to the presence of
a unique graft-versus-tumor effect in addition to the
high-dose chemoradiation used for both autoSCT and
alloSCT [1,2].
For patients whose autoSCT fails, the prognosis is
poor, and treatment options are limited. An alloSCT
is sometimes considered, but the results are disap-
pointing, and only a small number of patients beneﬁt
from this approach. The poor outcome of alloSCT in
this setting is typically due to high transplant-related
mortality (TRM) from the conventional myeloablative
transplantation regimens. In a large single-institution
report, 42 adult patients (17 years old) underwent
alloSCT after failure of an autograft, and the 2-year
disease-free survival and TRM were 8% and 70%,
respectively [3]. Recently, with the availability of long-
term follow-up results, therapy-related myelodyspla-
sia/acute myelogenous leukemia (t-MDS/AML) is in-
creasingly recognized as an important cause of late
treatment failure after autoSCT [4]. Although al-
loSCT is a potential curative treatment for this sub-
group of patients when it is performed after autolo-
gous transplantation, this is, again, associated with
high TRM, and there were few long-term survivors.
On the basis of these disappointing results, prior au-
toSCT is often considered an exclusion criterion for
alloSCT, particularly for adult patients and for those
who do not have an HLA-identical sibling.
Recent studies have demonstrated the feasibility
and efﬁcacy of reduced-intensity alloSCT for patients
with advanced hematologic malignancies who were
otherwise ineligible for an conventional SCT because
of age or comorbid medical conditions [5-7]. In an
attempt to reduce the regimen-related toxicity while
preserving the graft-versus-tumor effects, we studied a
reduced-intensity alloSCT approach for patients who
had a relapse or who developed t-MDS/AML after
their initial autoSCT. This report summarizes our
initial experience on 28 consecutive patients treated
with this approach.
PATIENTS AND METHODS
Eligibility and Definition
Between August 3, 1999, and June 6, 2002, 28
consecutive patients underwent reduced-intensity al-
loSCT after failure of a conventional autoSCT at the
City of Hope Comprehensive Cancer Center. This
study was approved by the institutional review board,
and informed consent was obtained. All patients un-
derwent a prior autoSCT and were considered ineli-
gible for conventional myeloablative alloSCT because
of a high risk of transplant-related death. Other eligi-
bility criteria included (1) creatinine clearance 60
mL/min, (2) total bilirubin 2 times normal, and (3)
Karnofsky performance score 70. HLA typing was
obtained by high-resolution polymerase chain reac-
tion sequence-speciﬁc primers for HLA class I and II
[8]. Donors and recipients were fully matched at HLA
A, B, C, and DRB1 in 23 pairs, and 5 had HLA class
I allele mismatches (1 related donor and 4 unrelated
donors). Patients with non-Hodgkin lymphoma were
classiﬁed according to the working formulation. Pa-
tients with Hodgkin lymphoma and non-Hodgkin
lymphoma were categorized as having treatment-re-
sponsive disease if they achieved a partial remission
after conventional salvage chemotherapy. Patients
with myeloid malignancy were classiﬁed as having
treatment-responsive disease if they achieved a remis-
sion or blast counts5% in the bone marrow without
circulating blasts after salvage chemotherapy.
Patient Characteristics
Patient characteristics and histories of prior SCTs
are summarized and detailed in Tables 1, 2, and 3.
The median age at alloSCT was 47 years (range,
18-65 years). There were 19 men and 9 women. The
conditioning regimen for the initial autoSCT con-
sisted of a total body irradiation–based regimen in 15
patients and a chemotherapy-based regimen in 13.
The median interval between autoSCT and disease
progression or development of t-MDS was 8 months
(range, 3-52 months). The median interval between
autoSCT and alloSCT was 15 months (range, 7-104
months). Diagnoses before alloSCT included 11 lym-
phoid disorders (non-Hodgkin lymphoma, n  7;
Hodgkin lymphoma, n  4), 11 myeloid disorders
(AML, n  9 [2 patients had preceding MDS]; MDS,
n  1; myeloproliferative disorder, n  1), 2 multiple
myelomas, and 4 t-MDS/AML (2 of the 4 patients had
concomitant relapsed low-grade non-Hodgkin lym-
phoma). Of the 7 patients with non-Hodgkin lym-
phoma, 3 had low-grade lymphoma and 4 had inter-
mediate-grade lymphoma according to the working
formulation. Of the 13 patients with Hodgkin lym-
phoma or non-Hodgkin lymphoma, 6 (Hodgkin lym-
phoma, n  1, non-Hodgkin lymphoma, n  5) had
histories of bone marrow involvement before al-
loSCT. Six patients had untreated disease, 10 patients
had treatment-responsive disease, and 12 had treat-
ment-refractory disease at the time of reduced-inten-
sity alloSCT. Nineteen patients (68%) had cytogenet-
ics checked before autoSCT and were normal. Of the
4 patients who had t-MDS/AML, 3 had cytogenetics
checked before autoSCT and were also normal.
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Treatment Characteristics and Evaluations
During the study period, there were 2 sequential
pilot studies evaluating the feasibility of reduced-in-
tensity alloSCT for patients who were not eligible for
a standard myeloablative transplantation performed in
our institution. In this report, we have included only
patients who experienced failure of a prior autologous
stem cell transplantation; the results of other patients
will be reported separately. The ﬁrst 4 patients were
treated with a preparative regimen of low-dose (2 Gy)
total body irradiation with or without ﬂudarabine (30
mg/m2/d for 3 days). Another 24 patients received
melphalan (140 mg/m2) with ﬂudarabine (25 mg/m2/d
for 5 days). Granulocyte colony-stimulating factor–
primed peripheral blood stem cells or bone marrow
was infused on day 0. The preferred stem cell source
for this study was peripheral stem cells, but 7 patients
received bone marrow because of donor (n  1; re-
lated donor) or collection center (n  6; unrelated
donor) preference. The rest of the 21 patients (13
related donors and 8 unrelated donors) received gran-
ulocyte colony-stimulating factor–mobilized periph-
eral blood stem cells. Fourteen patients received stem
cells from a related donor and 14 from an unrelated
donor. The median number of allogeneic CD34 cells
infused was 5.64  10 6/kg (range, 2.8-16.5  10
6/kg). Graft-versus-host disease (GVHD) prophylaxis
consisted of cyclosporine (CSA; 3 mg/kg intrave-
nously daily starting from day 1 and then tapered
gradually from day 60) and mycophenolate mofetil
(MMF; 15 mg/kg twice daily on days 0 to 28). Both
MMF and CSA were initially given intravenously but
were switched to the oral formulation when the pa-
tient was able to tolerate oral medications. CSA levels
were targeted to the upper therapeutic range (approx-
imately 700-1000 mg/mL) until day 28. For patients
who received a matched unrelated donor SCT, an
extended immunosuppressive regimen was used. CSA
tapering was started on day 100 after transplantation
only in the absence of active GVHD. Serial samples of
peripheral blood or bone marrow were monitored for
hematopoietic chimerism by using polymerase chain
reaction–based analyses of variable number tandem
repeats [9]. Acute and chronic GVHD were graded as
previously described [10,11]. Antimicrobial prophy-
laxis included levoﬂoxacin, low-dose amphotericin
(0.15 mg/kg/d), trimethoprim/sulfamethoxazole, and
acyclovir, according to our hospital guidelines. Mon-
itoring for cytomegalovirus viremia was performed
twice a week from day 21 to day 100 by using the shell
vial method. Patients with a positive culture were
started preemptively on ganciclovir or valganciclovir
for 6 weeks.
Statistical Analysis
Overall survival (OS) was measured from the date
of alloSCT to death, and event-free survival (EFS) was
Table 2. Transplant Characteristics
Variable n %
Donor type
Matched unrelated donor 14 50
Related donor 14 50
Graft source
PBSC 21 75
BM 7 25
GVHD prophylaxis: CSA/MMF 28 100
Median interval between auto-SCT and disease
progression
8 mo (range, 3-52)
Median interval between auto-SCT and alloSCT
15 mo (range, 7-116)
CSA indicates cyclosporine; MMF  mycophenolate; PBSC  pe-
ripheral blood stem cell; BM  bone marrow; autoSCT  autol-
ogous stem cell transplantation; alloSCT  allogeneic stem cell
transplantation; GVHD, graft-versus-host disease.
Table 1. Patient Characteristics*
Variable n %
Sex
Male 19 32
Female 9 68
Diagnosis
AML 9 32
MDS 1 4
MPD 1 4
MM 2 7
t-MDS/AML (2)† 14
NHL 7 25
HD 4 14
Conditioning at autoSCT
TBI/VP-16/Cytoxan 14 50
TBI/busulfan 2 7
BCNA/VP-16/Cytoxan 4 14
Bu/Cy 2 7
Bu/VP-16 1 4
Others‡ 5 18
Disease status at
AlloSCT
Untreated 6 21
Sensitive 10 36
Refractory 12 (RD6;MUD6) 43
CMV status
Positive 21 75
Negative 7 25
AML indicates acute myelogenous leukemia; MDS, myelodysplasia;
MPD, myeloproliferative disease; MM, multiple myeloma; t-
MDS/AML, therapy-related myelodysplasia or acute myeloge-
nous leukemia; NHL, non-Hodgkin lymphoma; HD, Hodgkin
disease; TBI, total body irradiation; VP-16, etoposide; Bu,
busulfan; Cy, cyclophosphamide; RD, related donor; MUD,
matched unrelated donor; CMV, cytomegclovirus.
*Median age at alloSCT: 47 (range, 18-65).
†Two patients had concomitant relapsed non-Hodgkin lymphoma.
‡One patient had 2 autoSCTs: melphalan for cycle 1 and Bu/Cy for
cycle II; 1 received BEAM, 1 received toxol/carboplatin/mitox-
antrone, and 1 received 2 cycles of melphalan.
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measured from transplantation to the date of con-
ﬁrmed progression, relapse, or death. Survival curves
were estimated by the method of Kaplan and Meier,
with signiﬁcance determined by the log-rank test.
Univariate analysis was performed to determine the
independent effects of various prognostic factors on
OS, EFS, relapse rate, and TRM. Factors examined
included type of donor (matched related versus unre-
lated), age at reduced-intensity SCT (analyzed as a
continuous variable), interval between initial autoSCT
and reduced-intensity SCT, prior total body irradia-
tion, stage of disease at the time of reduced-intensity
SCT (untreated, treatment responsive, or treatment
refractory), and diagnoses (myeloid disease versus
lymphoid disease). The statistical signiﬁcance of the
correlation between risk factors was examined by us-
ing the 2 test if each factor was categorical or the
Wilcoxon ranked sum test if 1 of the factors was
continuous. Two-sided P values resulting from the
proportional hazard regression models were derived
from theWald test, and no adjustments were made for
multiple comparisons. Data were analyzed as of July 3,
2003.
RESULTS
Engraftment and Toxicities
All patients engrafted and had 90% donor chi-
merism, as measured in the peripheral blood, bone
marrow, or both, on day 100 after SCT. T cell–,
granulocyte-, and monocyte-enriched subsets were
analyzed, yielding similar results. All 24 patients who
received the melphalan/ﬂudarabine regimen devel-
oped pancytopenia, and all of them achieved neutro-
phil engraftment. The median times to achieve an
absolute neutrophil count 500/L and 1000/L
were 13 days (range, 6-55 days) and 16 days (range,
7-58 days), respectively. Of these 24 patients, 21
achieved platelet transfusion independence, and the
median times to achieve platelet counts 20,000/L
and 50,000/L were 9 days (range, 6-62 days) and
Table 3. Outcome Data
Patient No. Age (y) Diagnosis Auto3PD (mo) Auto-Allo (mo) Dz Status BMT Type aGVHD/cGVHD Outcome
1 45 NHL (LG) 6 115 R MUD I/E NRM 4 mo
2 32 HD 7 11 S RD II/— PD
3 60 MPD 52 64 U RD I/E A 32 mo
4 44 MM 12 35 R RD II/E PD
5 54 AML/MDS 3 7 U MUD II/— A 15 mo
6 54 t-MDS/NHL (LG)* 25 100 S MUD IV/NA NRM 37 d
7 43 t-MDS 48 53 U RD 0/NA NRM 62 d
8 36 AML 6 10 S RD 0/NA A 7 mo
9 59 AML 9 15 R MUD II/— PD
10 54 MM 13 30 R RD IV/E A 19 mo
11 59 AML/MDS 12 15 R RD III/NA NRM 99 d
12 40 AML 5 10 S MUD 0/E A 24 mo
13 53 t-MDS/NHL (LG)* 22 30 S MUD II/E A 16 mo
14 52 NHL (LG) 9 21 R MUD III/NA NRM 69 d
15 30 AML 44 50 R MUD II/E A 14 mo
16 58 AML 5 7 S MUD 0/E A 28 mo
17 53 NHL (IG) 3 11 S RD II/— A 28 mo
18 32 AML 9 11 U MUD III/L A 27 mo
19 43 NHL (IG) 6 8 R RD 0/NA NRM 29 d
20 27 HD 8 13 R RD II/E A 31 mo
21 46 NHL (LG) 7 91 S RD II/E A 29 mo
22 46 AML 8 9 S MUD I/E NRM 6 mo
23 62 t-MDS 22 28 U RD I/E A 41 mo
24 66 MDS 9 14 U MUD I/E A 31 mo
25 59 NHL (IG) 19 51 R MUD 0/N NRM 22 d
26 18 HD 7 16 R MUD 0/E PD
27 58 NHL (IG) 3 9 R RD 0/— PD
28 42 HD 3 16 S RD 0/— A 12 mo
NHL indicates non-Hodgkin lymphoma; BMT, bone marrow transplantation, LG, low grade; IG, intermediate grade; HD, Hodgkin disease;
MPD, myeloproliferative disease; MM, multiple myeloma; t-MDS/AML, therapy-related myelodysplasia/acute myelogenous leukemia;
Auto3PD, interval between autoSCT and progressive disease; Auto-Allo, interval between autoSCT and alloSCT; Dz Status, disease
status before alloSCT; R, refractory; S, sensitive; U, untreated; MUD, matched unrelated donor SCT; RD, related donor SCT; NRM,
nonrelapse mortality; A, alive with no evidence of disease progression; aGVHD, acute graft-versus-host disease; cGVHD, chronic
graft-versus-host disease; E, extensive cGVHD; NA, not applicable.
*Patients 6 and 13 developed t-MDS 99 and 3 months after autoSCT, respectively. Neither received any treatment for t-MDS before alloSCT.
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13 days (range, 7-70 days), respectively. All 3 patients
who failed to achieve platelet transfusion indepen-
dence died before 100 days after SCT. Of the 4 pa-
tients who received the combination of low-dose total
body irradiation and ﬂudarabine, only 1 experienced
severe cytopenia after conditioning. This patient had
severe cytopenia from prior chemotherapy before
conditioning. The other 3 patients achieved a nadir at
a median of 10 days with a total white blood cell count
between 500 and 9000/L and with an absolute neu-
trophil count 1000/L at a median of 19 days after
SCT.
There were 6 early deaths from treatment-related
toxicity, with a day 100 nonrelapse mortality of 21%.
Overall, 8 patients (29%) in this cohort died of non-
relapse causes at last follow-up. Three died from
GVHD, 2 from interstitial pneumonitis/acute respi-
ratory distress syndrome, 1 from multiorgan failure, 1
from disseminated aspergillosis, and 1 from herpes
simplex encephalitis. Fifteen patients (54%) developed
grade II to IV acute GVHD, of which 6 (21%) had
grade III or IV acute GVHD. Among 21 evaluable
patients with 100 days of follow-up, 15 (67%) de-
veloped extensive chronic GVHD. In univariate anal-
ysis, the development of grade III to IV acute GVHD
(P  .02) and the use of bone marrow as the stem cell
source (P  .07) were associated with increased non-
relapse mortality. There were no statistically signiﬁ-
cant differences in nonrelapse mortality between do-
nor types (related versus unrelated donor; P  .72),
CD34 cell dose (P  .80), or the conditioning regi-
mens used for autoSCT (total body irradiation versus
chemotherapy based; P  .99). The 2-year Kaplan-
Meier projected nonrelapse mortality for patients who
received a bone marrow transplant versus a peripheral
stem cell transplant was 73.3% (95% conﬁdence in-
terval [CI], 62.7%-94.0%) versus 14.6% (95% CI,
0%-29.2%), respectively (log-rank; P  .05).
Relapse and Survival
Currently, 13 patients (46%) are alive with no
evidence of active disease; 7 patients (25%) developed
disease progression after alloSCT. With a median
follow-up of 24 months (range, 7-41 months) for the
surviving patients, the 2-year probabilities of OS,
EFS, and relapse were 56.5% (95% CI, 36.5%-
76.6%), 41.0% (95% CI, 21.0%-61.0%), and 41.9%
(95% CI, 18.1%-65.7%), respectively (Figures 1 and
2). In a Cox univariate regression analysis, refractory
disease at transplantation predicted inferior outcomes
when compared with treatment-responsive disease
and untreated disease (OS, P  .03; EFS, P  .01).
The 1-year probabilities of EFS for patients with
treatment-responsive disease, refractory disease, and
untreated disease were 59.3% (95% CI, 23.5%-
95.5%), 11.1% (95% CI, 0%-38.0%), and 71.4%
(95% CI, 38%-100.0%), respectively (untreated/
treatment-responsive disease versus refractory disease;
log-rank test; P  .005; Figure 3). Patients with my-
eloid disease also tended to have improved EFS and
less post-alloSCT disease progression when compared
with patients with lymphoid disease (P  .07 and .03,
Figure 1. Overall survival and event-free survival (n  28). Figure 2. Time to relapse (n  28).
Figure 3. Event-free survival: untreated or sensitive disease versus
resistant disease.
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respectively). The 1-year probabilities of EFS for pa-
tients with lymphoid disease and myeloid disease were
19.6% (95% CI, 0%-44.3%) and 65.4% (95% CI,
37%-93.6%), respectively (log-rank test; P .05; Fig-
ure 4). The 1-year probabilities of EFS were 36.7%
(95% CI, 9.1%-64.3%) and 47.6% (95% CI, 20.1%-
75.1%) for patients who received a related donor al-
loSCT versus an unrelated donor alloSCT, respec-
tively (log-rank test; P .89). The 1-year probabilities
of OS for patients who received a bone marrow trans-
plant and a peripheral blood stem cell transplant were
21.4% (95% CI, 0%-56.3%) and 74.2% (95% CI,
54.2%-94.0%), respectively (log-rank test; P  .05;
Figure 5).
DISCUSSION
The prognosis of patients who experience a failed
prior autologous SCT is poor. Most of these patients
will die of their original disease shortly after the re-
lapse. In a report from the European Bone Marrow
Transplant Registry, the 2-year survival was 11% in a
group of patients with acute leukemia who were
treated with salvage chemotherapy after an autograft
failure [12]. In the same report, 90 patients underwent
a subsequent myeloablative alloSCT; the estimated
2-year survival was 32%. A single-institution study
from Radich et al. [3] reported a 2-year disease-free
survival of 23% for 59 patients with various hemato-
logic malignancies who underwent a conventional al-
logeneic SCT after failure of their initial autoSCT.
However, it is noteworthy that in both series, the
beneﬁts of this approach were limited to younger
patients. In Radich’s series, the 2-year survival for
patients aged 17 years was 8%. Similar results were
reported from other trials that showed treatment-
related mortality of 50% to 70% [13-15]. This se-
verely limited the success of this approach. In this
series of patients with a reduced-intensity approach,
the day 100 nonrelapse mortality was 21% despite a
median age of 47 years and inclusion of 14 (50%)
patients who underwent unrelated SCT. The esti-
mated 2-year probabilities of OS, EFS, and relapse
rate after the reduced-intensity SCT were 56.5%,
41.0%, and 41.9%, respectively. The results from this
cohort compared favorably to those from the Euro-
pean Bone Marrow Transplant Registry [12] and the
Fred Hutchinson Cancer Research Center [3]. Al-
though the favorable outcomes could be due to better
patient selection, they are most likely secondary to the
reduced-intensity conditioning regimen combined
with the use of MMF and CSA as GVHD prophylaxis.
Similar results were observed in 2 recently pub-
lished reports. In a multi-institutional retrospective
study from the British group, 38 patients with lym-
phoproliferative malignancies whose prior autoSCT
failed underwent a reduced-intensity alloSCT with an
alemtuzumab-containing regimen [16]. The actuarial
OS and progression-free survival at 14 months were
53% and 50%, respectively. The estimated TRM
rates were 7.9% and 20% at 100 days and 14 months
after alloSCT, respectively. In another report from
the Spanish group, 43 patients with progressive he-
matologic malignancies after a prior autoSCT and 4
patients with secondary MDS/AML underwent trans-
plantation with a melphalan- or busulfan-based re-
duced-intensity regimen [17]. The 1-year cumulative
incidence of TRMwas 24%.With a median follow-up
of 358 days, the 1-year OS and progression-free sur-
vival were 63% and 57%, respectively.
In contrast, Devine et al. [18] described 11 pa-
tients (median age, 41 years) who relapsed after auto-
SCT or alloSCT and received second transplants
from HLA-identical or -mismatched related donors
with a regimen similar to our protocol. Ten of 11
patients died at a median of 140 days after the trans-
plantation. Five died from relapse and 5 from nonre-
lapse causes. Because only 1 of the patients was in a
Figure 5. Overall survival: bone marrow versus peripheral blood
stem cells (PBSC).
Figure 4. Event-free survival: lymphoid disease versus myeloid
disease.
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complete remission at the time of SCT, this may
account for the inferior outcome when compared with
other series. In our study, the 1-year probabilities of
disease-free survival for patients with refractory dis-
ease, sensitive disease, and untreated disease were
11%, 51.8%, and 75.4%, respectively. Not surpris-
ingly, our data suggested that the beneﬁt of reduced-
intensity allogeneic stem cell transplantation for pa-
tients with refractory disease is very limited. In
another report from a multi-institutional study, 45
patients with various hematologic malignancies un-
derwent nonmyeloablative allogeneic stem cell trans-
plantation with the combination of low-dose radiation
and ﬂudarabine as a conditioning regimen after failure
of a prior autoSCT or alloSCT [19]. With a median
follow-up of 7.9 months, 22 (49%) patients were alive
and 12 (27%) were alive and disease free. Day 100 and
overall nonrelapse mortality occurred among 5 (11%)
and 11 (24%) patients, respectively. Of note, the
transplants were well tolerated, and many of the treat-
ment failures were disease related.
Various reduced-intensity conditioning regimens
have been studied, and these reports demonstrated the
feasibility of this approach, in particular, regarding
engraftment. However, none of these regimens has
shown superiority over other regimens. Of note, the
initial report from Giralt et al. [6], which used either
(1) ﬂudarabine, idarubicin, and cytarabine or (2)
cladribine and cytarabine as a conditioning regimen,
suggested that engraftment was possible in some pa-
tients but that patients with refractory disease had
rapid recurrences. On the basis of this observation, we
decided to test the combination of high-dose melpha-
lan and ﬂudarabine as the preparative regimen in our
patients with advanced disease. However, it is unclear
whether there was any beneﬁt in using a more inten-
sive regimen.
In a collaborative effort by the Fred Hutchinson
Cancer Research Center, Stanford University, and the
City of Hope, a phase III randomized study suggested
that peripheral blood stem cell transplantation offered
a survival advantage when compared with bone mar-
row transplantation for patients undergoing a myelo-
ablative transplantation, in particular, for patients with
advanced disease [20]. Thus, in this study we used
peripheral stem cells whenever possible. Although pa-
tients who received a peripheral stem cell transplant
tended to have less treatment-related death when
compared with the bone marrow transplant patients in
this analysis, the data should be interpreted cautiously
because of the small number of patients in the bone
marrow group. In addition, 6 of 7 patients from the
bone marrow group received stem cells from an un-
related donor because of collection center preference.
This might inﬂuence the transplantation outcomes,
but in this analysis, donor type did not predict for
outcome.
In our cohort, patients with myeloid malignancies
tended to have an improved outcome. This is in ac-
cordance with the results obtained from Radich et al.
[3] when pediatric patients were treated with a con-
ventional myeloablative transplantation. In this study,
most patients with lymphoid malignancies underwent
their autoSCT for treatment relapses, whereas most
patients with myeloid malignancies underwent auto-
SCT at the ﬁrst complete remission, which may ac-
count for the differences in outcome. In contrast, the
British group [16] and the Spanish group [17] had
reported very promising results in patients with lym-
phoid malignancies who underwent a reduced-inten-
sity alloSCT after their initial autoSCT failed. How-
ever, it is noteworthy that approximately three
quarters of the patients in both series had myeloma,
Hodgkin lymphoma, or low-grade lymphoma. Longer
follow-up will be required to assess the outcomes of
these patients whose disease may have a more indolent
clinical course. However, we are very encouraged by
the results of patients with myeloid malignancies
whose autoSCT failed in our study.
Although follow-up is short, reduced-intensity al-
loSCT seems to be an effective treatment for patients
who experienced failure of a prior autoSCT. The
regimen is well tolerated with an acceptable toxicity
proﬁle in patients who have experienced previous
treatment failure with an autoSCT, including those
who underwent unrelated donor SCT. The 100-day
nonrelapse mortality of 21% compares favorably with
a second myeloablative alloSCT. On the basis of this
observation, prior failure of an autoSCT should not be
used as a criterion to exclude patients from alloSCT
who would otherwise be expected to have a poor
outcome.
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